A Study on TAK-279 for Ulcerative Colitis
Phase 2
207
about 3.4 years
18–75
16 sites in CA, FL, GA +7
About this study
Researchers are testing whether TAK-279 can reduce bowel inflammation and symptoms in people with moderately to severely active ulcerative colitis. The trial also compares any medical problems that participants experience when taking TAK-279 or a placebo, and how well they tolerate these problems.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take TAK-279
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change From Baseline in Disease-Specific Health-related Quality of Life (HRQoL) as Measured by IBDQ Total Score at Week 12, Change From Baseline in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12, Percentage of Participants With no Abdominal Pain at Week 12
Gastroenterology